Genprex raised $6.4 million in IPO at a share price of $5.
Unlike most of the commercial blockbuster lung cancer immunotherapies, its unique lead candidate, Oncoprex® targets advanced lung cancer treatment.
You have read of your 8 free articles this month.
Subscribe to
Medgenera All-Access
Enjoy unlimited access to all contents, resources, exclusive market research reports, databases, surveys and many more features by subscribing to Medgenera All-Access.
Access articles & resources worth up to US $4, 000 per month.
Register with your email to read the full article.
This article is FREE for you! Unlock the unlimited access by subscribing to Medgenera All-Access.
More in GROW
GROW
7 New Ideas to Start a Healthcare Business in India (2018)
Seven new #healthcare #business ideas in India in 2018. Which one would you prefer to pursue?
BRIEFING
This Cancer Biotech Startup Raises Over 40% Higher in IPO than Proposed Goal
The cancer startup develops novel immunotherapies that target the immune-suppressive tumor microenvironment to attack cancer. The company is developing immuno-oncology drugs which could be combined with existing immunotherapies to enhance the efficiency of detecting and killing cancer cells.
GROW
Genprex Raises $6.4 M in IPO, Could Bring “Game-Changing” Immuno-Gene Therapy for Advanced Lung Cancer
Genprex raised $6.4 million in IPO at a share price of $5. Unlike most of the commercial blockbuster lung cancer immunotherapies, its unique lead candidate, Oncoprex® targets advanced lung cancer treatment.
GROW
J&J Establishes First JLABS in Europe to Help Healthcare Startups
KEY POINTS First JLABS established in Europe at the Beerse Janssen R&D Campus. Belgium-based JLINX incubator will transition to global ...
Most Popular
GROW
7 New Ideas to Start a Healthcare Business in India (2018)
Seven new #healthcare #business ideas in India in 2018. Which one would you prefer to pursue?
NEWLY PUBLISHED
Pharma Patents: Can India Reward Incremental Innovation?
Leave a reply